Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD) and Evaporative Dry Eye Disease (DED)

Next Previous
Trial Profile

A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD) and Evaporative Dry Eye Disease (DED)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZR-MD-001 (Primary)
  • Indications Dry eyes; Meibomian gland dysfunction
  • Focus Therapeutic Use
  • Sponsors Azura Ophthalmics

Most Recent Events

  • 20 Apr 2023 According to an Azura Ophthalmics media release, data from this study will be featured at the upcoming Annual Meetings for the Association for Research in Vision and Ophthalmology (ARVO) and in the American Society of Cataract and Refractive Surgery (ASCRS) 2023.
  • 09 Dec 2022 Primary endpoint has been met. (Ocular Surface Disease Index (OSDI) score), according to an Azura Ophthalmics media release.
  • 09 Dec 2022 Results published in the Azura Ophthalmics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top